{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-007294","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.613693+00:00","generated_at":"2026-06-18T07:00:33.307942+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"VYNE reports FY2022 net loss $23.2M; VYN201 Phase 1b in vitiligo dosing","bullets":["GAAP net loss of $23.2M for FY2022 vs $73.3M in 2021; adjusted net loss $18.9M.","Topline Phase 1b data for VYN201 (pan-BD BET inhibitor) in vitiligo expected mid-2023.","Positive preliminary Phase 1a safety data for VYN201; three doses selected for Phase 1b.","Regained Nasdaq minimum bid price compliance after 1-for-18 reverse stock split in Feb 2023.","VYN202 option agreement extended to April 2023; IND-enabling studies planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-007294","json":"https://secwatch.observer/filing/0001628280-23-007294.json","markdown":"https://secwatch.observer/filing/0001628280-23-007294.md","text":"https://secwatch.observer/filing/0001628280-23-007294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000162828023007294/0001628280-23-007294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000162828023007294/mnlo-20230309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:00:33.307942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"78af219039126475490b965c5f151a883bcbbdae","claim":"VYNE Therapeutics Inc. reported financial results for year ended December 31, 2022.","evidence_excerpt":"On March 9, 2023, VYNE Therapeutics Inc. issued a press release announcing its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000162828023007294/0001628280-23-007294-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}